» Articles » PMID: 14634005

The VCAM-1 Gene That Encodes the Vascular Cell Adhesion Molecule is a Target of the Sry-related High Mobility Group Box Gene, Sox18

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2003 Nov 25
PMID 14634005
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

VCAM-1 (vascular cell adhesion molecule-1) and Sox18 are involved in vascular development. VCAM-1 is an important adhesion molecule that is expressed on endothelial cells and has a critical role in endothelial activation, inflammation, lymphatic pathophysiology, and atherogenesis. The Sry-related high mobility group box factor Sox18 has previously been implicated in endothelial pathologies. Mutations in human and mouse Sox18 leads to hypotrichosis and lymphedema. Furthermore, both Sox18 and VCAM-1 have very similar spatio-temporal patterns of expression, which is suggestive of cross-talk. We use biochemical techniques, cell culture systems, and the ragged opossum (RaOP) mouse model with a naturally occurring mutation in Sox18 to demonstrate that VCAM-1 is an important target of Sox18. Transfection, site-specific mutagenesis, and gel shift analyses demonstrated that Sox18 directly targeted and trans-activated VCAM-1 expression. Importantly, the naturally occurring Sox18 mutant attenuates the expression and activation of VCAM-1 in vitro. Furthermore, in vivo quantitation of VCAM-1 mRNA levels in wild type and RaOP mice demonstrates that RaOP animals show a dramatic and significant reduction in VCAM-1 mRNA expression in lung, skin, and skeletal muscle. Our observation that the VCAM-1 gene is an important target of SOX18 provides the first molecular insights into the vascular abnormalities in the mouse mutant ragged and the human hypotrichosis-lymphedema-telangiectasia disorder.

Citing Articles

The blood vasculature instructs lymphatic patterning in a SOX7-dependent manner.

Chiang I, Graus M, Kirschnick N, Davidson T, Luu W, Harwood R EMBO J. 2023; 42(5):e109032.

PMID: 36715213 PMC: 9975944. DOI: 10.15252/embj.2021109032.


Low Efficacy of Genetic Tests for the Diagnosis of Primary Lymphedema Prompts Novel Insights into the Underlying Molecular Pathways.

Bonetti G, Paolacci S, Samaja M, Maltese P, Michelini S, Michelini S Int J Mol Sci. 2022; 23(13).

PMID: 35806420 PMC: 9267137. DOI: 10.3390/ijms23137414.


A transcription factor is the target of propranolol treatment in infantile hemangioma.

Schrenk S, Boscolo E J Clin Invest. 2022; 132(3).

PMID: 35104803 PMC: 8803321. DOI: 10.1172/JCI156863.


Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma.

Seebauer C, Graus M, Huang L, McCann A, Wylie-Sears J, Fontaine F J Clin Invest. 2021; 132(3).

PMID: 34874911 PMC: 8803322. DOI: 10.1172/JCI151109.


Transcription Factor Control of Lymphatic Quiescence and Maturation of Lymphatic Neovessels in Development and Physiology.

Tabrizi Z, Ahmed N, Horder J, Storr S, Benest A Front Physiol. 2021; 12:672987.

PMID: 34795596 PMC: 8593113. DOI: 10.3389/fphys.2021.672987.